teniposide (Vumon)

Introduction

Tradename: Vumon.

Indications

• treatment of refractory childhood, acute lymphocytic leukemia (ALL) in combination with other antineoplastic agents
• non-Hodgkin's lymphoma
• neuroblastoma

Dosage

Injection:

• formulated in polyethoxlated castor oil & dehydrated alcohol (43%): 10 mg/mL (5 mL)

Solution:

• solutions containing 0.5-2 mg/mL remain stable for 4 hours & those containing 0.1-0.2 mg/mL remain stable for 6 hours

Adverse effects

• common (> 10%)
  • myelosuppression, leukopenia, neutropenia, thrombocytopenia, mucositis, nausea/vomiting, diarrhea, infection
• less common (1-10%)
  • alopecia, rash, hypotension, hypersensitivity, fever, hemorrhage
• uncommon (< 1%)
  • hepatic dysfunction, peripheral neurotoxicity, renal dysfunction, metabolic abnormalities

Drug interactions

• plasma clearance of methotrexate may be slightly increased
• salicylate, sulfamethoxazole & tolbutamide displace teniposide from protein binding sites to a small, but significant extent

Laboratory

test interactions: increases serum K+

Mechanism of action

• mitotic inhibitor
• topoisomerase inhibitor

More general terms

• epipodophyllotoxin
• antimitotic agent; mitotic inhibitor (antineoplastic agent)

Additional terms

• acute lymphoblastic leukemia (ALL)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=34698
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5396
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5311475
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5284623
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=452548
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=275784